TY - JOUR
T1 - Heat-denatured human immunodeficiency virus type 1 protein 24 antigen
T2 - Prognostic value in adults with early-stage disease
AU - Sterling, Timothy R.
AU - Hoover, Donald R.
AU - Astemborski, Jacquie
AU - Vlahov, David
AU - Bartlett, John G.
AU - Schupbach, Jorg
N1 - Funding Information:
Financial support: Swiss Federal Office of Public Health, Swiss Human Immunodeficiency Virus Cohort Study/Swiss National Science Foundation (grant 3345-062041); National Institute on Drug Abuse (grants RO-1 DA04334 and RO-1 DA08009); National Institute of Allergy and Infectious Diseases (grant K23 AI01654).
PY - 2002/10/15
Y1 - 2002/10/15
N2 - CD4+ lymphocyte count and human immunodeficiency virus (HIV) type 1 RNA level are useful for determining when to initiate antiretroviral therapy but are not used widely in developing countries due to the high cost. Heat-denatured protein 24 (p24) antigen is an inexpensive assay that predicts disease progression among persons with advanced disease but has not been assessed among persons with early-stage disease. Plasma levels of heat-denatured p24 antigen were quantified in baseline study-visit specimens obtained from injection drug users enrolled in a longitudinal cohort study of HIV-1 infection. Of the 494 study participants (median initial CD4+ lymphocyte count, 518 lymphocytes/mm3), 90 (18%) progressed to acquired immunodeficiency syndrome within 5 years. p24 antigen level correlated with both CD4+ lymphocyte count (r = -0.34; P< .0001) and HIV-1 RNA level (r = 0.55; P< .0001). p24 antigen level >5 pg/mL predicted disease progression, comparable with that of cutoff CD4+ lymphocyte count <350 lymphocytes/mm3 and HIV-1 RNA level >30,000 copies/mL. Heat-denatured p24 antigen level predicted subsequent clinical disease progression in early-stage HIV-1 infection and correlated with both CD4+ lymphocyte count and HIV-1 RNA level.
AB - CD4+ lymphocyte count and human immunodeficiency virus (HIV) type 1 RNA level are useful for determining when to initiate antiretroviral therapy but are not used widely in developing countries due to the high cost. Heat-denatured protein 24 (p24) antigen is an inexpensive assay that predicts disease progression among persons with advanced disease but has not been assessed among persons with early-stage disease. Plasma levels of heat-denatured p24 antigen were quantified in baseline study-visit specimens obtained from injection drug users enrolled in a longitudinal cohort study of HIV-1 infection. Of the 494 study participants (median initial CD4+ lymphocyte count, 518 lymphocytes/mm3), 90 (18%) progressed to acquired immunodeficiency syndrome within 5 years. p24 antigen level correlated with both CD4+ lymphocyte count (r = -0.34; P< .0001) and HIV-1 RNA level (r = 0.55; P< .0001). p24 antigen level >5 pg/mL predicted disease progression, comparable with that of cutoff CD4+ lymphocyte count <350 lymphocytes/mm3 and HIV-1 RNA level >30,000 copies/mL. Heat-denatured p24 antigen level predicted subsequent clinical disease progression in early-stage HIV-1 infection and correlated with both CD4+ lymphocyte count and HIV-1 RNA level.
UR - http://www.scopus.com/inward/record.url?scp=0037108665&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037108665&partnerID=8YFLogxK
U2 - 10.1086/343807
DO - 10.1086/343807
M3 - Article
C2 - 12355373
AN - SCOPUS:0037108665
SN - 0022-1899
VL - 186
SP - 1181
EP - 1185
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 8
ER -